Oracle and AstraZeneca Join Forces on AI-Driven Health Care Innovation
TECHWORLD ·
✦ AI Summary
Oracle and AstraZeneca have signed a nonbinding agreement for the use of AI and real-world data (RWD).
The two companies will pursue efforts to help health care professionals identify eligible patients, accelerate evidence generation, and bring research insights into routine care.
To this end, they will combine AstraZeneca's scientific and therapeutic expertise with Oracle's capabilities in medical data, cloud, AI, analytics, and clinical workflow support.
Oracle and AstraZeneca have signed a nonbinding agreement. The deal is aimed at using AI and real-world data (RWD), and the two companies will pursue cooperation to connect clinical trials and clinical practice.
The two companies plan to support health care professionals in identifying patients eligible to participate in clinical trials and to pursue faster evidence generation, while also exploring ways to bring research insights into routine care. To this end, they will combine AstraZeneca's expertise in science and therapeutics with Oracle's capabilities in medical data, cloud, AI, analytics, and clinical workflow support.
The two companies will review specific use cases for the latest applications and AI. The goal of the review is to improve clinical trial efficiency and contribute to clinical trial success.
The collaboration is expected to help health care professionals identify eligible patients more quickly and conveniently, while also improving access for patients who need clinical trials and helping address patient recruitment challenges.
The CEOs of the two companies said the core of the collaboration lies in combining each company's strengths. AstraZeneca CEO Pascal Soriot said the partnership represents a global collaboration between leading health care and AI companies to accelerate everything from drug discovery to patient care. He said AstraZeneca's world-class scientific capabilities will be combined with Oracle's data and technology expertise. He added that this could help health care professionals identify suitable patients earlier, support clinical trial optimization, and enable continuous evidence generation across the entire life cycle of medicines.
Oracle CEO Mike Sicilia said health care is one of the areas where AI can deliver significant value. He said using data more effectively can connect scientific innovation to better patient outcomes. He added that combining AstraZeneca's scientific expertise with Oracle's data, cloud, AI, and health care capabilities would accelerate research. He also said more patients would have opportunities to participate in clinical trials, and that related insights would be delivered more quickly to clinical settings.
AstraZeneca and Oracle plan to explore a continuous learning model that applies insights from clinical research and routine care to future study design, as well as to safety monitoring and patient treatment.
To this end, the two companies plan to establish a joint governance framework and create reusable technology components. They also plan to agree on performance metrics and evaluate outcomes using those agreed metrics.
Based on the previous stages, the two companies will review the possibility of expanding the successful approach to other diseases and to other regions.
Source: TECHWORLD · Lee Gwang-jae
Original: https://www.epnc.co.kr/news/articleView.html?idxno=408505
References
This article was produced with the help of an automated content generation algorithm.
Source: TECHWORLD
View originalThis article was summarized and organized by BizCrush based on the original article from TECHWORLD. For exact quotations and full details, please refer to the original article.